The new public protector says she will leave the dispute over the state capture report prepared by h.
SIAYA, KENYA - A mother watched with dread as a nurse inserted a tube in her baby's head. Blood streamed into the anemic 4-month-old who already had malaria. the mosquito-borne disease that kills a million African children every year.
"Malaria is one of the deadliest sicknesses for children," the nurse said - words that sent the young mother into a crumpled heap on the bed beside her wide-eyed baby boy, wrapped in a blue-and-yellow floral blanket.
There is new hope, however, in this verdant area where President Barack Obama's relatives live. A vaccine that appears to be able to prevent the disease in about 50percent of children is now undergoing the final stage of testing.
If regulators determine it is safe, it could be on the market in three to five years - the first vaccine against a human parasite.
Tens of millions of Africans are plagued by malaria every year, and more than a third of the hospital beds in this rural Kenyan region next to Lake Victoria are dedicated to its victims. More than one million children die of the disease in Africa annually, a crippling economic drain that prolongs disease and poverty on the continent.
Malaria is also prevalent in parts of Asia, the Middle East and Central and South America.
This vaccine was developed specifically for Africa and will only prevent the African strain of the disease. Experts say it would be a historic advancement.
"Some may say, '50percent, that's not great'. And that's true.
"But if you get a measles vaccine, you're not going to get measles again," said Dave Jones, a US Army colonel and director of a clinic in nearby Kombewa operated by the Walter Reed Army Institute of Research and the Kenya Medical Research Institute.
"When you consider we lose one million kids a year, if you could cut that in half it would be a great step forward."
Experts from around the globe are meeting in the Kenyan capital Nairobi as part of the fifth pan-African malaria conference, and a news conference isscheduled this week.
More than $500 million has been spent on the combined efforts by drug maker GlaxoSmithKline and the PATH Malaria Vaccine Initiative, which is funded by the Bill & Melinda Gates Foundation.
The goal is to immunise children against malaria during their youngest high-risk years, and then for them to develop their own natural immunities.
No prices have been set for the vaccine, though families in Africa may not have to pay anything for it. - Sapa-AP